 Current drug therapies for CLLSLL are known to increase the severity of pre-existing low blood cell counts, which in turn increase the risk of infections in patients. Research to improve the safety and effectiveness of CLLSLL therapy is currently ongoing. One such therapy being investigated is Rituximab. 